Syneos Health Collaborates with Microsoft to Accelerate AI Across the Clinical to Commercial Continuum
Syneos Health (Nasdaq:SYNH) announced a multi-year collaboration with Microsoft to enhance clinical trial and commercial program efficiencies using AI technology. The partnership aims to leverage Microsoft Azure services to develop an advanced analytics platform that facilitates faster data processing and better resource allocation. With this AI-driven approach, Syneos Health intends to improve site selection and reduce patient enrollment timelines, ultimately expediting the delivery of therapies. This collaboration aligns with Syneos' goal of using technology to boost healthcare outcomes.
- Strategic multi-year agreement with Microsoft for AI collaboration.
- Development of an advanced analytics platform to enhance clinical trial efficiency.
- Ability to process and analyze data quickly for better resource allocation.
- Improved site selection and reduced enrollment timelines for clinical trials.
- None.
Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance
MORRISVILLE, N.C., March 20, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced a strategic multi-year agreement with Microsoft. Utilizing Microsoft Azure services, Syneos Health has developed an advanced analytics platform that enables agile deployment of machine learning (ML) supporting the analysis, design and execution of clinical trials and commercial programs worldwide.
The multi-year agreement includes collaboration with Microsoft Research and leverages developments from OpenAI. Through this collaboration, Syneos Health will deliver technology and data solutions with Microsoft that accelerate clinical development and elevate commercial performance for biopharma customers.
Based on this AI-enabled platform, Syneos Health is able to process and analyze data to fast-track timelines, optimize resource allocation and unlock clinical trial efficiencies. These capabilities will allow for superior site selection and reduced enrollment timelines to bring new treatments to patients faster.
“Microsoft is the ideal technology partner for Syneos Health,” said Michelle Keefe, CEO, Syneos Health. “Their clear industry leadership in AI and their pragmatic approach to improving healthcare outcomes for patients, science and industry is completely aligned with our value proposition. We look forward to a strong relationship for years to come – one that drives innovative solutions to accelerate our customers’ success.”
“We are pleased to work with Syneos Health to bring our expertise in AI together with their solutions to help make a meaningful difference in the lives of patients,” said Patty Obermaier, Vice President, U.S. Health and Life Sciences, Microsoft. “Syneos Health’s integration of Azure Synapse Analytics, Azure Data Factory, Azure SQL Database, and other Azure services, allows them to develop a platform that empowers biopharma customers to deliver therapies to patients faster.”
About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.
We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.
Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
| Syneos Health Contacts: | ||
| Investor Relations Ronnie Speight Senior Vice President, Investor Relations +1 919 745 2745 Investor.Relations@syneoshealth.com | Press/Media Gary Gatyas Executive Director, External Communications +1 908 763 3428 gary.gatyas@syneoshealth.com | |
FAQ
What is the new partnership announced by Syneos Health?
How will the collaboration with Microsoft benefit Syneos Health?
What technology is Syneos Health using in its partnership with Microsoft?
What are the expected outcomes of Syneos Health's AI collaboration?
What does the AI-enabled platform developed by Syneos Health do?
